Covance Acquires Antibodies Product Line Of Sternberger Monoclonals
Princeton, New Jersey, June 27, 2005
— Covance Inc. ( NYSE: CVD
) today announced that its wholly owned subsidiary, Covance Research Products Inc., has acquired the complete line of antibodies developed by Sternberger Monoclonals Inc. (SMI), of Lutherville, MD. These products are ideally suited for immunohistochemical studies and complement Covance's extensive suite of antibody products for neuroscience and neurodegenerative disease research and discovery.
As a subsidiary of one of the world's largest and most comprehensive drug development services companies, Covance Research Products is uniquely positioned to support the Sternberger antibodies suite. The company supports biomedical scientists with a select catalog of antibody products, including leading products in the areas of neuroscience, epitope tags, and cell biology. In addition, for the last several years, Covance has produced the Sternberger antibodies under contract for SMI.
The Sternberger products, as well as the existing portfolio of Covance antibodies, are now available to researchers worldwide through Covance's on-line store, store.crpinc.com
. Technical support and customer service is available by phone (800 922-2226 within the United States, or +1.510 704-0140 internationally), or by email to email@example.com
Covance Inc., with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1 billion, global operations in 17 countries, and approximately 6,800 employees worldwide. Information on Covance's products and services, recent press releases , and SEC filings can be obtained through the Covance website.
Statements contained in this press release, which are not historical facts, are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including the statements contained herein regarding anticipated trends in the Company's business are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, levels of industry research and development spending, the Company's ability to continue to attract and retain qualified personnel, the fixed price nature of contracts or the loss of large contracts, and other factors described in the Company's filings with the Securities and Exchange Commission.
Covance and the Covance logo are registered service marks of Covance in the United States and other countries.